Personalised Immunotherapy NEOGAP Therapeutics AB is a privately held clinical-stage biopharmaceutical focused on personalised cancer immunotherapy, specifically developing pTTL using patient-derived cells, which suggests opportunities for strategic collaborations, supplier partnerships, and clinical trial engagement with cancer centers and CROs.

Clinical Stage Growth The company is advancing a Phase I/II trial in advanced colorectal cancer, indicating a near-term window for partnering on trial logistics, patient recruitment support, biomarker collaboration, and potential co-development or licensing discussions as data matures.

Strategic Partnerships Recent partnerships and grants with Vinnova, Weill Cornell Medicine, and NorthX Biologics signal openness to collaboration, manufacturing scale-up, and cross-border funding opportunities that can be leveraged to propose joint development programs and tech-transfer arrangements.

Manufacturing Readiness With a strategic CDMO collaboration in place (NorthX Biologics) and a focus on customised cell therapy, there is a clear need for advanced manufacturing solutions, regulatory support, and scalable GMP-ready processes to meet clinical and potential commercialization timelines.

Financial Trajectory Funding of SEK 87 million in 2026 and ongoing grant support indicate growing financial runway, presenting an opportunity to discuss multi-year partnerships, grant-funded projects, and milestone-driven collaborations with potential risk-sharing models.